Bristol Myers Wins FDA Approval for Zenbexus, Debuting New Myeloma Drug Class
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
The clearance of Zenbexus is the first for a group of protein-degrading 'CELMoD' molecules, expanding treatment options for patients with this challenging condition.
Bristol Myers Squibb
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene“The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.”
stat news — STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class